These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19920928)

  • 1. Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex.
    Brull SJ; Naguib M
    Drug Des Devel Ther; 2009 Sep; 3():119-29. PubMed ID: 19920928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sugammadex, the first selective relaxant binding agent for neuromuscular block reversal.
    Stair C; Fernandez-Bustamante A
    Drugs Today (Barc); 2012 Jun; 48(6):405-13. PubMed ID: 22745926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
    Ren WH; Jahr JS
    Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.
    Hristovska AM; Duch P; Allingstrup M; Afshari A
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012763. PubMed ID: 28806470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incomplete recovery from rocuronium-induced muscle relaxation in patients with amyotrophic lateral sclerosis using sugammadex: A case report.
    Chun HR; Chung J; Kim NS; Kim AJ; Kim S; Kang KS
    Medicine (Baltimore); 2020 Jan; 99(3):e18867. PubMed ID: 32011508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent.
    Welliver M; McDonough J; Kalynych N; Redfern R
    Drug Des Devel Ther; 2009 Feb; 2():49-59. PubMed ID: 19920893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sugammadex - indications and clinical use.
    Sokół-Kobielska E
    Anaesthesiol Intensive Ther; 2013; 45(2):106-10. PubMed ID: 23877905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sugammadex: another milestone in clinical neuromuscular pharmacology.
    Naguib M
    Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sugammadex: A revolutionary drug in neuromuscular pharmacology.
    Nag K; Singh DR; Shetti AN; Kumar H; Sivashanmugam T; Parthasarathy S
    Anesth Essays Res; 2013; 7(3):302-6. PubMed ID: 25885973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Muscle Relaxants and Reversal Agents in a Setting Without Cost Restrictions: Experience from a Tertiary Academic Hospital in the Netherlands.
    Martini CH; Honing GHM; Bash LD; Olofsen E; Niesters M; van Velzen M; Dahan A; Boon M
    Ther Clin Risk Manag; 2022; 18():379-390. PubMed ID: 35422624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugammadex reversal of muscle relaxant blockade provided less Post-Anesthesia Care Unit adverse effects than neostigmine/glycopyrrolate.
    Chang HC; Liu SY; Lee MJ; Lee SO; Wong CS
    J Formos Med Assoc; 2022 Dec; 121(12):2639-2643. PubMed ID: 35577643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparing for the unexpected: special considerations and complications after sugammadex administration.
    Iwasaki H; Renew JR; Kunisawa T; Brull SJ
    BMC Anesthesiol; 2017 Oct; 17(1):140. PubMed ID: 29041919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sugammadex: A Scientific Review Including Safety and Efficacy, Update on Regulatory Issues, and Clinical Use in Europe.
    Jahr JS; Miller JE; Hiruma J; Emaus K; You M; Meistelman C
    Am J Ther; 2015; 22(4):288-97. PubMed ID: 25299637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sugammadex: a selective relaxant-binding agent providing rapid reversal.
    Rex C; Bergner UA; Pühringer FK
    Curr Opin Anaesthesiol; 2010 Aug; 23(4):461-5. PubMed ID: 20489603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Algorithm-based preventive strategies for avoidance of residual neuromuscular blocks].
    Unterbuchner C; Ehehalt K; Graf B
    Anaesthesist; 2019 Nov; 68(11):744-754. PubMed ID: 31650189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex.
    Martinez-Ubieto J; Ortega-Lucea S; Pascual-Bellosta A; Arazo-Iglesias I; Gil-Bona J; Jimenez-Bernardó T; Muñoz-Rodriguez L
    Minerva Anestesiol; 2016 Jul; 82(7):735-42. PubMed ID: 26472231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do we really need sugammadex as an antagonist of muscle relaxants in anesthesia?
    Meistelman C; Donati F
    Curr Opin Anaesthesiol; 2016 Aug; 29(4):462-7. PubMed ID: 27168088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
    Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
    Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment.
    Chambers D; Paulden M; Paton F; Heirs M; Duffy S; Craig D; Hunter J; Wilson J; Sculpher M; Woolacott N
    Health Technol Assess; 2010 Jul; 14(39):1-211. PubMed ID: 20688009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: Successful Reversal of Residual Block with Sugammadex in a Patient Not Known to Have Myasthenia Gravis.
    Kuo KC; Wong CS; Wu TJ
    Am J Case Rep; 2022 Oct; 23():e937128. PubMed ID: 36229945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.